NASDAQ:CLLS
Cellectis S.A. Stock News
$2.99
-0.0499 (-1.64%)
At Close: May 17, 2024
Cellectis S.A. (EPA:ALCLS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
10:00am, Friday, 08'th May 2020
Cellectis S.A. (EPA:ALCLS) just released its quarterly report and things are looking bullish. The results were...
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2020
08:30pm, Wednesday, 06'th May 2020
Proprietary allogeneic CAR T-cell programs on track in Phase 1 dose escalation trials; AMELI-01 in r/r AML patients, BALLI-01 in r/r B-ALL patients and MELANI-01 in r/r MM.
Gilead, Takeda Rumored to Have Sights on Iovance
10:13pm, Thursday, 30'th Apr 2020
Potential suitors looking to expand their work in cancer likely covet company's technology Continue reading...
Gilead, Takeda Rumored to Have Sights on Iovance
09:24pm, Thursday, 30'th Apr 2020
Gilead, Takeda Rumored to Have Sights on Iovance, Stocks: IOVA,GILD,TAK,CLLS, release date:Apr 30, 2020
Cellectis to Hold First Quarter 2020 Earnings Call on Thursday, May 7, 2020 at 7:30 AM EDT
08:30pm, Wednesday, 29'th Apr 2020
NEW YORK, April 29, 2020 -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on.
Bio Roundup: Alnylam's Billions, COVID-19 Vaccines, Moma Debuts & More
01:28pm, Friday, 17'th Apr 2020
The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn't the only way for biotech companies to
Ex-Celgene Exec Brownstein Named Chief Medical Officer of Cellectis
09:38pm, Monday, 13'th Apr 2020
Cellectis (NASDAQ: ]) has appointed Carrie Brownstein to serve as its chief medical officer. She worked most recently at Celgene as vice president of
Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer
08:30pm, Monday, 13'th Apr 2020
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced
Allogene Therapeutics: Revisiting Its Prospects 5 Months On
07:24am, Monday, 30'th Mar 2020
Since my last article on Allogene Therapeutics about 5 months ago, its share price has fallen by around 30%. I was bearish on the company’s short-term prospects
Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash Position
02:02pm, Wednesday, 25'th Mar 2020
Sangamo has announced several impressive partnerships with global biotech and big pharma companies. Its recent deal with Biogen gives it ~$700M cash on hand, at
Iovance Biotheraputics: Still Well-Poised To Treat Solid Tumors
04:38am, Friday, 20'th Mar 2020
Since my last article on Iovance Biotherapeutics about 4 months, its share price went up by more than 75% on buyout rumors, before crashing back down with the C
BTIG's stocks for the storm
09:30pm, Sunday, 15'th Mar 2020
News is free at Seeking Alpha.This post is a Notable Call. Notable Calls are a Premium feature.To access this and other Notable Calls, try a free trial to Seeking Alpha Premium.
Head-To-Head Survey: Autolus Therapeutics (NASDAQ:AUTL) & Iovance Biotherapeutics (NASDAQ:IOVA)
06:34am, Friday, 13'th Mar 2020
Autolus Therapeutics (NASDAQ:AUTL) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of
Celyad: Early Stage CAR-T Company With A Different Approach
02:55pm, Wednesday, 11'th Mar 2020
Celyad is developing both an autologous and allogeneic CAR-T platform to treat both hematological malignancies and solid tumors. Its lead allogeneic product can
US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis
08:30pm, Tuesday, 10'th Mar 2020
US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis
